Four years after paying $1.26 billion to bring aboard the gout drug Zurampic (lesinurad), Astrazeneca plc's decision to let Ironwood Pharmaceuticals Inc. pay $100 million for the since-approved therapy amounted to "largely a strategic question at the corporate level" of the pharma giant, said Ironwood CEO Peter Hecht.